Vivus’ Qsymia Sales Still Slim, Even As Costs Bulge
This article was originally published in The Pink Sheet Daily
Executive Summary
The obesity drug maker is pulling out all the stops to make its drug more accessible to patients, but several roadblocks still stand in the way of the drug banking meaningful sales revenue. Meanwhile, the launch and a post-marketing trial of Qsymia are adding up in terms of cost.